POMC and hypophysitis: A previous report described dysfunction in the secretion of thyroid-stimulating hormone (TSH), ACTH, LH/follicle-stimulating hormone (FSH), and PRL in 92.0%, 74.0%, 85.7%, and 67.7% of ipilimumab-induced hypophysitis cases, respectively [8], whereas dysfunction in TSH secretion was only observed in two of four nivolumab cases, and no cases exhibited dysfunction in LH/FSH secretion.